Loading…
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $117M | $14M | $5M | $-1M | 3.5% | 10.2% | -58.4% |
| 2024 | $106M | $18M | $12M | $-7M | 12.3% | -6.8% | - |
| 2023 | $113M | $20M | $-93M | $17M | -666.2% | 10.9% | -4137.1% |
| 2022 | $102M | $10M | $2M | $6M | 3.2% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 102.29 | 113.45 | 105.76 | 116.59 |
| Cost Of Revenue | 4.79 | 4.64 | 3.88 | 5.42 |
| Gross Profit | 97.50 | 108.81 | 101.87 | 111.17 |
| Operating Expense | 88.29 | 89.60 | 85.64 | 99.68 |
| Operating Income | 9.20 | 19.21 | 16.23 | 11.49 |
| EBITDA | 10.33 | 20.33 | 17.82 | 14.01 |
| EBIT | 9.20 | 19.21 | 16.23 | 11.49 |
| Pretax Income | 9.41 | -76.97 | 23.22 | 14.44 |
| Tax Provision | 5.10 | 8.52 | 5.32 | 4.56 |
| Net Income | 2.30 | -92.93 | 12.09 | 5.03 |
| Net Income Common Stockholders | 2.30 | -92.93 | 12.09 | 5.03 |
| Total Expenses | 93.09 | 94.24 | 89.53 | 105.10 |
| Interest Expense | 0.04 | 0 | 0 | 0 |
| Interest Income | 0.71 | 1.04 | 1.55 | 1.75 |
| Research And Development | 16.69 | 13.78 | 12.02 | 13.70 |
| Selling General And Administration | 71.61 | 75.82 | 73.62 | 85.98 |
| Normalized EBITDA | 10.33 | 116.03 | 10.72 | 11.31 |
| Normalized Income | 2.30 | -17.33 | 6.61 | 3.18 |
| Basic EPS | 0.03 | -1.41 | 0.14 | 0.06 |
| Diluted EPS | 0.03 | -1.41 | 0.05 | 0.02 |
| Tax Effect Of Unusual Items | 0 | -20.10 | 1.63 | 0.85 |
| Tax Rate For Calcs | 0.21 | 0.21 | 0.23 | 0.32 |
| Total Unusual Items | 0 | -95.70 | 7.10 | 2.70 |
| Total Unusual Items Excluding Goodwill | 0 | -95.70 | 7.10 | 2.70 |
| Net Income From Continuing Operation Net Minority Interest | 2.30 | -92.93 | 12.09 | 5.03 |
| Reconciled Depreciation | 1.13 | 1.11 | 1.59 | 2.52 |
| Reconciled Cost Of Revenue | 4.79 | 4.64 | 3.88 | 5.42 |
| Net Interest Income | 0.73 | 1.04 | 1.55 | 1.75 |
| Net Income From Continuing And Discontinued Operation | 2.30 | -92.93 | 12.09 | 5.03 |
| Total Operating Income As Reported | 9.20 | -67.23 | 16.16 | 11.49 |
| Diluted Average Shares | 76.58 | 65.83 | 102.29 | 103.18 |
| Basic Average Shares | 76.58 | 65.83 | 85.09 | 89.34 |
| Diluted NI Availto Com Stockholders | 2.30 | -92.93 | 12.09 | 5.03 |
| Minority Interests | -2.01 | -7.45 | -5.81 | -4.85 |
| Net Income Including Noncontrolling Interests | 4.31 | -85.48 | 17.90 | 9.88 |
| Net Income Continuous Operations | 4.31 | -85.48 | 17.90 | 9.88 |
| Other Income Expense | -0.52 | -97.22 | 5.44 | 1.20 |
| Other Non Operating Income Expenses | -0.52 | -1.52 | -1.66 | -1.50 |
| Special Income Charges | 0 | -86.44 | -0.07 | 0 |
| Gain On Sale Of Ppe | 0 | -0.63 | -0.07 | 0 |
| Gain On Sale Of Business | 0 | -2.71 | 0 | 0 |
| Other Special Charges | 0 | 83.10 | 0 | 0 |
| Gain On Sale Of Security | 0 | -9.26 | 7.17 | 2.71 |
| Net Non Operating Interest Income Expense | 0.73 | 1.04 | 1.55 | 1.75 |
| Total Other Finance Cost | -0.73 | -1.04 | 0 | 0 |
| Interest Expense Non Operating | 0.04 | 0 | 0 | 0 |
| Interest Income Non Operating | 0.71 | 1.04 | 1.55 | 1.75 |
| Other Operating Expenses | -0.84 | 0 | 0 | 0 |
| Selling And Marketing Expense | 54.24 | 61.16 | 57.51 | 65.18 |
| General And Administrative Expense | 17.37 | 14.66 | 16.11 | 20.80 |
| Other Gand A | 17.37 | 14.66 | 16.11 | 20.80 |
| Operating Revenue | 102.29 | 113.45 | 105.76 | 116.59 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Gyre Therapeutics, Inc.this co. | GYRE | $713M | 367.50↑ premium | 6.33 | 3.5% | 46.81 |
| BioAge Labs, Inc. | BIOA | $749M | - | 2.32 | -29.6% | -5.11 |
| Castle Biosciences, Inc. | CSTL | $734M | - | 1.53 | -5.1% | -224.72 |
| Absci Corporation | ABSI | $732M | - | 3.77 | -60.8% | -5.15 |
| CBLL | CBLL | $729M | - |
| 4.65 |
| -34.4% |
| -10.30 |
| Allogene Therapeutics, Inc. | ALLO | $726M | - | 1.65 | -65.3% | -1.79 |
| Enhabit, Inc. | EHAB | $704M | - | 1.31 | -0.8% | 13.72 |
| Solid Biosciences Inc. | SLDB | $694M | - | 3.09 | -96.8% | -2.97 |
| Ironwood Pharmaceuticals, Inc. | IRWD | $683M | 27.67 | -2.58 | -9.2% | 8.78 |
| Peer Median | - | 27.67 | 1.99 | -32.0% | -4.04 | |